High Blood Pressure Risk and Your Genetics

Written by Scott Peeples, BS Biomedical Sciences · ExomeDNA Founder Reviewed by ExomeDNA Editorial Process Last reviewed: May 26, 2026

High blood pressure — essential hypertension — is the single largest modifiable risk factor for heart attack, stroke, and kidney disease, affecting more than 1 billion people worldwide. DNAJC1, FGD5, MRAS, and PDE3A are among the genetic signals identified for essential hypertension in a genome-wide analysis of 282,871 UK Biobank participants using time-to-event statistical methods that detected loci missed by conventional case/control approaches.^[1] Below: how the genetic architecture of blood pressure intersects with vascular biology, and what population research reveals about inherited hypertension susceptibility.

What is essential hypertension?

Essential (or primary) hypertension is elevated blood pressure without an identifiable secondary cause — as opposed to secondary hypertension driven by renal artery stenosis, aldosterone-producing tumors, or specific endocrine disorders. Essential hypertension accounts for approximately 90–95% of all hypertension cases and is the dominant form studied in population genetics.

Blood pressure is determined by cardiac output (how much blood the heart pumps per minute) and peripheral vascular resistance (the resistance arterial walls offer to blood flow). Hypertension arises when either or both are chronically elevated. The kidneys regulate sodium and water retention, directly influencing blood volume and cardiac output. Arterial smooth muscle regulates vascular tone through constriction and relaxation. The sympathetic nervous system and renin-angiotensin-aldosterone system modulate both in response to stress, salt intake, and circadian signals.

The time-to-event framing of this hypertension trait means the genetic data analyzed not just who develops hypertension but when — capturing age of onset and time to clinical detection across 282,871 UK Biobank participants. This survival analysis approach is more sensitive to genetic variants influencing hypertension onset trajectory than standard case/control analysis, and accounts for the gradual accumulation of blood pressure risk over decades rather than a binary yes/no phenotype.

The genetics of high blood pressure

The genetic landscape of hypertension is highly polygenic: hundreds of loci distributed across the genome each contribute small effects that in aggregate shape blood pressure trajectories across a lifetime. The top genetic signals identified in the time-to-event analysis reflect vascular signaling, Rho GTPase biology, and cyclic nucleotide phosphodiesterase pathways — mechanistically distinct routes through which inherited variation shapes blood pressure regulation.^[1]

611 disease-associated loci across 12 common diseases were identified in 282,871 UK Biobank participants using SPACox (Bi et al. 2020, American Journal of Human Genetics), a time-to-event genome-wide method — including 38 loci that would have been missed by conventional binary case/control approaches, demonstrating additional genetic architecture captured by analyzing hypertension onset timing rather than binary affected-versus-unaffected classification.^[1]

DNAJC1, encoding a DnaJ family molecular chaperone (Hsp40 class), appears as the top-ranked genetic signal for essential hypertension at this locus on chromosome 10. Molecular chaperones broadly govern protein folding and cellular stress responses; the specific mechanism by which this locus influences blood pressure regulation is not yet fully characterized, reflecting the broad cellular biology that large GWAS captures as signals ahead of full mechanistic resolution. FGD5 — FYVE, RhoGEF, and PH domain containing 5 — is a guanine nucleotide exchange factor for Rho GTPases expressed selectively in endothelial cells, where it activates Cdc42-mediated signaling governing endothelial cell morphology, vascular barrier function, and angiogenic responses. Variants near FGD5 in hypertension GWAS data implicate endothelial Rho/Cdc42 biology as a heritable component of blood pressure regulation.

PDE3A encodes a cyclic nucleotide phosphodiesterase that degrades cAMP and cGMP in vascular smooth muscle cells, directly regulating vasodilation — and gain-of-function mutations in PDE3A cause autosomal dominant hypertension with brachydactyly, establishing a direct mechanistic link between PDE3A-driven cAMP/cGMP signaling loss and inherited elevated blood pressure; common GWAS variants near PDE3A in this analysis capture more subtle shifts in the same vascular smooth muscle relaxation pathway.^[1]

MRAS — muscle RAS proto-oncogene — is a Ras-family GTPase expressed in cardiac and vascular smooth muscle, where it activates MAPK/ERK signaling pathways relevant to smooth muscle cell function, vascular remodeling, and cardiac hypertrophy. MRAS variants have appeared across multiple cardiovascular GWAS. NME9, appearing at the same chromosome 3 locus as MRAS, is a nucleoside diphosphate kinase family member whose specific role in this hypertension signal is less characterized, likely reflecting co-localization at the MRAS GWAS peak.

What the research says

Research base: Moderate. The genetic basis of this hypertension phenotype is supported by the SPACox genome-wide time-to-event analysis of 282,871 UK Biobank participants across 12 common diseases (Bi et al. 2020, American Journal of Human Genetics), identifying 611 loci including novel hypertension signals not detectable by conventional binary GWAS.^[1] Moderate confidence reflects that hypertension genetics is extensively established in the broader field — with hundreds of confirmed loci from multiple large GWAS — but the specific loci from this time-to-event analysis require independent replication to confirm novel findings. The underlying analysis focused on white British European-ancestry participants; the genetic architecture of hypertension shows ancestral variation, and effect sizes may differ in other populations. See our methodology page for how we evaluate and apply genetic evidence in your ExomeDNA profile.

How high blood pressure genetics affects health

Hypertension is the leading modifiable risk factor for cardiovascular disease worldwide. Chronically elevated blood pressure damages arteries through mechanical stress: sustained high-pressure blood flow induces endothelial injury, promotes arterial wall thickening, accelerates atherosclerotic plaque development, and increases cardiac afterload, gradually driving left ventricular hypertrophy over years of sustained elevation. The downstream consequences include stroke, myocardial infarction, heart failure, chronic kidney disease, and retinal vascular damage.

The genetic risk captured here reflects inherited susceptibility to hypertension onset — a higher genetic risk score corresponds to greater inherited tendency toward earlier or more pronounced blood pressure elevation. The genetic score does not determine whether hypertension develops, as lifestyle factors including diet, physical activity, body weight, and alcohol intake have large modifiable effects that substantially interact with genetic background over a lifetime.

The vascular biology genes in this landscape — FGD5 governing endothelial Rho/Cdc42 signaling, MRAS regulating vascular smooth muscle MAPK pathways, and PDE3A controlling cAMP/cGMP degradation in smooth muscle — collectively illuminate how inherited variation in the cellular machinery of vascular tone regulation shapes long-term blood pressure trajectories. These are not abstract distant associations but mechanistically grounded signals in the tissues directly responsible for arterial resistance and vasodilation.

Working with your blood pressure result

What research suggests about blood pressure management

• Sodium intake and diet: dietary sodium is the most studied environmental blood pressure modifier; the DASH diet (low-sodium, high-potassium, rich in fruits, vegetables, and low-fat dairy) has the strongest population evidence base for blood pressure reduction of any dietary pattern.^[1]
• Regular aerobic exercise: consistent aerobic activity (150+ minutes per week at moderate intensity) reduces resting systolic blood pressure by approximately 4–9 mmHg on average — comparable to the effect of a single antihypertensive medication class.
• Body weight management: adiposity drives hypertension through sodium retention, sympathetic activation, and systemic inflammation; weight reduction is among the most impactful modifiable blood pressure interventions.
• Alcohol moderation: heavy alcohol intake is a direct pressor; reductions in alcohol consumption reliably reduce blood pressure in heavy drinkers.
• Stress and sleep: chronic psychological stress and short sleep duration both activate the sympathetic nervous system and renin-angiotensin-aldosterone system, sustaining blood pressure elevation over time.
• Regular blood pressure monitoring: home or clinical measurement provides the actual blood pressure value that genetics complements — clinical thresholds for intervention are based on measured values, not genetic risk estimates alone.

Related traits and genes

High blood pressure risk connects directly to Cardiovascular Disease Risk and Stroke Risk — hypertension is the primary modifiable driver of both, making the genetics of blood pressure a core cardiovascular risk trait in the ExomeDNA profile. Atherosclerosis Risk reflects the arterial damage pathway through which hypertension causes long-term cardiovascular injury.

For kidney health, Chronic Kidney Disease Risk is a direct downstream consequence of sustained hypertension — the kidneys are simultaneously a cause and a major target organ of elevated blood pressure. Heart Failure Risk reflects the cardiac consequence of years of elevated afterload. Arterial Stiffness connects the FGD5 and MRAS vascular smooth muscle biology to the biomechanical arterial changes that accompany hypertension progression over time.

Frequently asked questions

What makes essential hypertension "essential" versus secondary?

Essential (primary) hypertension has no identifiable single cause — it arises from the aggregate effect of genetic susceptibility, lifestyle factors, dietary patterns, and aging on the blood pressure regulatory system. Secondary hypertension, accounting for only 5–10% of cases, has a specific identifiable cause such as renal artery stenosis, primary aldosteronism, or thyroid disease and is treated by addressing the underlying cause. The genetic architecture captured here reflects essential hypertension — where hundreds of genetic variants each contribute small effects on cardiac output, vascular resistance, and neurohormonal regulation.

What does the time-to-event design add to hypertension genetics?

Conventional GWAS asks whether someone develops hypertension (binary yes/no). Time-to-event analysis incorporates both whether and when — age of onset and time-to-clinical detection. This approach is more sensitive to variants influencing hypertension onset trajectory, particularly those affecting early-onset risk or the rate of blood pressure progression over decades. The SPACox method identified 38 loci not detectable by binary case/control approaches across 12 diseases, suggesting that analyzing hypertension onset timing reveals genetic architecture that standard methods miss.

How does PDE3A connect to blood pressure regulation?

PDE3A encodes a cyclic nucleotide phosphodiesterase expressed in vascular smooth muscle cells that degrades cAMP and cGMP — the second messengers that activate protein kinase A and G to drive vasodilation. When cAMP and cGMP are degraded by PDE3A, the pro-relaxation signal is terminated, maintaining vascular tone. Gain-of-function PDE3A mutations that degrade cAMP more aggressively reduce vasodilatory signaling, causing inherited hypertension with brachydactyly syndrome. The common variants near PDE3A in population GWAS represent more subtle shifts in the same smooth muscle relaxation pathway.

What does FGD5 do in blood pressure biology?

FGD5 is a guanine nucleotide exchange factor that activates Rho family GTPases — particularly Cdc42 — in endothelial cells. Endothelial Cdc42 signaling governs cell morphology, barrier function, and angiogenic responses. Variants near FGD5 in hypertension GWAS data implicate endothelial vascular biology as a heritable component of blood pressure regulation, reflecting how the endothelial lining's ability to respond to shear stress and produce vasodilatory signals like nitric oxide shapes arterial tone over time.

How does a higher genetic risk score relate to actual blood pressure?

A higher genetic risk score reflects greater inherited susceptibility to developing elevated blood pressure — not a certainty that hypertension will develop. Population-level genetic risk scores predict hypertension onset and severity in aggregate, but for any individual the outcome depends heavily on lifestyle factors. Diet, physical activity, body weight, and alcohol intake each have substantial independent effects on blood pressure that modify genetic susceptibility significantly. Blood pressure is shaped by the interaction of genetic background with decades of lifestyle and environmental exposures.

References

1. Bi W, et al. (2020). A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank. Am J Hum Genet. PMID: 32589924. DOI: 10.1016/j.ajhg.2020.06.003.

Data sources:

• GWAS Catalog (NHGRI-EBI, accessed 2026-05-26)
• Open Targets Platform (CC0 1.0, accessed 2026-05-26)
• ClinVar (NCBI, accessed 2026-05-26) — entries at ≥2-star review status
• ClinGen Gene-Disease Validity (CC0 1.0, accessed 2026-05-26)

This page is published by the ExomeDNA Research Team. Last reviewed: 2026-05-26.